A second-generation M1-polarized CAR macrophage with …
2023年11月27日 · Here the authors design a second-generation macrophage-specific CAR by integrating CD3ζ and toll/IL-1R (TIR) domains resulting in an M1-polarized CAR-iMAC with …
CAR macrophages on a fast track to solid tumor therapy
2024年1月2日 · Expressing chimeric antigen receptors (CARs) in macrophages has led to promising results in preclinical and clinical work. Now, induced pluripotent stem cells have …
CAR-macrophage: An extensive immune enhancer to fight cancer
2021年11月30日 · The chimeric antigen receptor (CAR) has become a promising approach to increase the cancer recognition capacity of immune cells. Based on their ability to penetrate …
A new era of macrophage-based cell therapy - Nature
2023年9月1日 · Macrophages are essential innate immune cells found throughout the body that have protective and pathogenic functions in many diseases. When activated, macrophages …
Human chimeric antigen receptor macrophages for cancer ... - PubMed
We found that a chimeric adenoviral vector overcame the inherent resistance of primary human macrophages to genetic manipulation and imparted a sustained pro-inflammatory (M1) …
CAR-macrophage: A new immunotherapy candidate against solid tumors
Chimeric antigen receptor (CAR)-T cell therapy has been shown to be an effective treatment for hematological tumors, but the treatment of solid tumors still lacks effectiveness. In the tumor …
CAR-macrophage: An extensive immune enhancer to fight cancer. Tumour-associated macrophages (TAMs) are the most abundant innate immune cells and constitute up to 50% of …
CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage ...
2022年3月31日 · This comprehensive review article will discuss the current status and the major hurdles associated with CAR T and CAR NK therapy, followed by the structure and cutting …
Advancing CAR-based immunotherapies in solid tumors: CAR- macrophages …
2023年11月28日 · In this review, we briefly outlined the applications of macrophages or neutrophils in adoptive cell therapies, and focused on chimeric antigen receptor (CAR) …
CAR-macrophage: A new immunotherapy candidate against solid tumors
2021年7月1日 · Until November 2020, two clinical trials based on the CAR-M strategy have been approved by the FDA. The first is a drug candidate from CARISMA Therapeutics, CT-0508, …
- 某些结果已被删除